We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

3 hedge funds and large institutions have $441K invested in Benitec Biopharma in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 3 → 3 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

41% less capital invested

Capital invested by funds: $743K → $441K (-$302K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$3.17K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$119K
2
EAM
Evanson Asset Management
California
-$2K
3
TRCT
Tower Research Capital (TRC)
New York
-$396
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$438K -$119K -300 -18%
UBS Group
2
UBS Group
Switzerland
$2K +$3.17K +8 New
TRCT
3
Tower Research Capital (TRC)
New York
$1K -$396 -1 -20%
EAM
4
Evanson Asset Management
California
– -$2K -86 Closed

BNTC Hedge Fund Activity: Q2 2016 in Review

3 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q2 2016, worth a combined $441K — down 41% from $743K a quarter earlier.

Fund positioning in BNTC was balanced in Q2 2016: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 2 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $3.17K. The largest seller was Sabby Management, cutting an estimated $119K.

  • 3 institutional investors held Benitec Biopharma (BNTC) as of Q2 2016, unchanged from Q1 2016.
  • Funds reported $441K of Benitec Biopharma stock for Q2 2016, down 41% quarter-over-quarter.
  • 1 fund opened new Benitec Biopharma positions in Q2 2016 and 1 closed out, a net change of 0 holders.
  • The largest Benitec Biopharma buyer in Q2 2016 was UBS Group, an estimated $3.17K added.
  • The largest Benitec Biopharma seller in Q2 2016 was Sabby Management, an estimated $119K sold.

Based on aggregated 13F filings for Q2 2016.